CLK3

CLK3 (PF3D7_1114700) is an essential cyclin-dependent-like protein kinase of Plasmodium falciparum that functions as a key regulator of spliceosome activity across the parasite life cycle (PMID:31467193, PMID:42363832). As a kinase, its full catalytic activity requires phosphorylation at tyrosine Y526 in its activation loop (PMID:22127061), and it phosphorylates SR (serine/arginine-rich) proteins — PfSRSF12, PfSFRS4, and PfSF-1 — specifically through their Arg/Ser-rich (RS) domains, since an RS-domain-deleted PfSF-1 peptide is not a substrate (PMID:25188378). Consistent with this role in pre-mRNA splicing regulation, CLK3 localizes to both the nucleus and cytoplasm in asexual blood stages and gametocytes (PMID:25188378). CLK3 is essential for survival at multiple life stages — asexual blood stage, liver stage, and gametocyte development — and its selective inhibition causes transcriptome-wide mis-splicing, with intron retention and over 2,000 aberrant splice junctions across more than 1,000 genes involved in essential processes (PMID:31467193, PMID:35921477, PMID:42363832). The kinase has been chemogenetically validated as the target of the selective inhibitor TCMDC-135051 (PMID:31467193, PMID:42345078), and structural analysis has defined its catalytic site, including a Cys368 poorly conserved in the human kinome and a catalytic Lys394, both of which can be covalently engaged by inhibitors with nanomolar parasiticidal potency (PMID:35921477, PMID:39441986, PMID:40521344).

1. 2011 Medium

   Establishing how CLK3 catalytic activity is switched on, phospho-proteomics identified an activation-loop tyrosine whose phosphorylation is essential for full kinase activity.

   Evidence Global phospho-proteomic analysis with functional validation of the Y526 site

   PMID:22127061

   Open questions at the time

   • The upstream kinase responsible for Y526 phosphorylation is not identified
   • Whether Y526 phosphorylation is regulated across life stages is unknown
2. 2014 Medium

   To define what CLK3 acts on, in vitro kinase assays showed it phosphorylates SR proteins through their RS-rich domains, linking the kinase to the splicing machinery, and localization placed it in both nucleus and cytoplasm.

   Evidence In vitro kinase assays with recombinant SR protein substrates plus an RS-domain-deletion control; immunofluorescence localization in asexual and gametocyte stages

   PMID:25188378

   Open questions at the time

   • Substrate phosphorylation shown in vitro but not confirmed in vivo
   • Cellular consequence of SR protein phosphorylation not yet demonstrated
3. 2019 High

   To establish essentiality and therapeutic relevance, chemogenetic target validation confirmed CLK3 as the target of TCMDC-135051 and showed its inhibition kills parasites at multiple life stages while down-regulating hundreds of essential genes, consistent with a splicing role.

   Evidence Selective chemical inhibition with analog-sensitive/chemogenetic validation, transcriptomics, and multi-stage assays including P. berghei and P. knowlesi

   PMID:31467193

   Open questions at the time

   • Transcriptional down-regulation was measured but direct splicing defects were not yet resolved here
   • Mechanistic connection between kinase activity and specific splicing events not established at this stage
4. 2022 Medium

   To connect kinase inhibition to a defined molecular outcome, structural analysis mapped the catalytic site and RNA-seq showed that inhibition (by altiratinib and TCMDC-135051) causes global splicing disruption dominated by intron retention.

   Evidence Genetic target deconvolution, structural analysis of the catalytic site, RNA sequencing, and resistance-mutation mapping

   PMID:35921477

   Open questions at the time

   • Which SR-protein phosphorylation events drive the observed intron retention is not directly resolved
   • No full-length co-crystal structure reported in this study
5. 2024 High

   To enable durable covalent inhibition, a co-crystal structure with TCMDC-135051 revealed a Cys368 poorly conserved in the human kinome, and covalent inhibitors targeting it showed nanomolar potency with washout-resistant efficacy.

   Evidence Co-crystal structure determination, covalent inhibitor design, recombinant kinase assays, and parasite growth assays with 6-hour washout

   PMID:39441986

   Open questions at the time

   • In vivo efficacy and selectivity of Cys368-targeting covalent inhibitors not yet established
   • Resistance liability of covalent engagement not characterized
6. 2026 High

   To resolve the scale of the splicing defect and confirm inhibitor selectivity, transcriptome-wide RNA-seq quantified mis-splicing across >1,000 genes, and orthogonal chemical proteomics confirmed TCMDC-135051 as a selective CLK3 inhibitor within the parasite kinome.

   Evidence RNA-seq of inhibitor-treated wild-type versus resistant parasites (2,039 mis-spliced junctions across 1,125 genes); chemical pulldown and thermal proteome profiling for selectivity

   PMID:42345078 PMID:42363832

   Open questions at the time

   • Direct catalytic mechanism linking CLK3 activity to each mis-spliced junction not resolved
   • Whether mis-splicing is a direct kinase effect or a downstream consequence not fully separated
7. 2026 Medium

   To expand the covalent targeting strategy, structure-based design engaged the catalytic Lys394 with benzaldehyde warheads, establishing a covalent site distinct from Cys368.

   Evidence Structure-based drug design with protein mass spectrometry confirmation of Lys394 adduct, recombinant kinase assays, and parasite growth assays

   PMID:40521344

   Open questions at the time

   • Comparative advantage of Lys394 versus Cys368 targeting not established
   • In vivo activity of Lys394-covalent compounds not reported

• How CLK3-mediated SR protein phosphorylation is mechanistically coupled to specific spliceosome assembly and intron-retention events, and how CLK3 activity is regulated across the life cycle, remains open.
• In vivo substrate phosphorylation map not established
• Upstream regulators of Y526 phosphorylation unknown
• Direct link between individual SR-protein phosphosites and specific splicing outcomes not demonstrated